Private equity and venture capital firms are increasingly aware of the fact that legislation and policies established in the US and the EU directly influence the value of their investments. Investment firms turn to Tiber Creek Partners for providing detailed analysis identifying and assessing global government procurement trends as well as best-practices to mitigate the risks associated with investing in companies that receive U.S. federal and state funding and government contracts.
We understand the issues that affect companies in the public health sector, because we helped create this industry. We understand how government agencies operate and how to predict and affect the funding that is available for the programs of interest to life science companies. Thus, for the investment community, we are able to forecast government priorities and needs – as well as identify federal and state funding available to the biodefense, pharmaceutical, vaccine, and diagnostics industries. This knowledge and experience uniquely positions Tiber Creek Partners to provide political intelligence and industry analysis to the investment community.
Our multi-disciplinary approach allows us to speak to the strength of company portfolios and proposed technical solutions. Our team members regularly assist clients with their forecasts, due diligence reviews and investment transactions. We regularly assist our clients as they pursue opportunities in the rapidly expanding government-focused efforts in the businesses and industries associated with homeland security, global health, biotech and pharmaceutical R&D.
Issues that routinely impact our clients and their financial investors include:
Our experience in representing the investment community – as well as the companies in which they invest – helps us assist both investors and our company clients in obtaining, evaluating, and structuring their financing, while minimizing their risk.
Our team tracks all relevant funding opportunities and related procurement developments by the Department of Health and Human Services (HHS) and its agencies including the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), and Centers for Disease Control (CDC); the Department of Defense (DoD), the Department of Homeland Security (DHS), and various EU agencies. The team also monitors and categorizes follow-on regulations and actual notices of procurement. In addition to assessing publicly announced solicitations, the team also targets specific agency organizational elements where unsolicited proposals (what industry thinks the government needs) will be most favored and accepted. We strategize and oversee the preparation of such unsolicited proposals, as well as responses to Requests for Information (RFIs) and Requests for Proposals (RFPs). Furthermore, Tiber Creek identifies and establishes opportunities for public-private partnerships (PPPs) and private-academic partnerships between companies and research universities, which create funding and partnership opportunities for our clients.
Tiber Creek Partners’ team includes Ph.D.’s in molecular biology and biochemistry and a Master’s degree in statistics that are successfully used to assist clients with a wide range of projects and inquiries. Thus, Tiber Creek Partners possesses the ability to translate the underlying science of our clients’ technologies and marry it to the appropriate government programs, requirements, priorities and funding opportunities. We assist clients in navigating the intersection between business objectives, public policy and scientific advancement. In this capacity, we ensure that client technology is aligned with requirements and/or objectives of the government, and identify individuals within appropriate federal agencies who will become internal champions for the technology. As part of this process, we also perform substantial due diligence on competitors and their positioning in order to ensure a comprehensive understanding of the industry landscape. The goal for all of our clients is to ensure that government support, whether financial, regulatory, or legislative, is geared toward the commercial objectives and the bottom-line of the client. Our positioning between government and industry makes us uniquely suited to advance novel technologies through our in depth scientific review and substantive government experience.
Our team advises and assists clients with implementing both domestic and global marketing plans, including arranging meetings with health and defense ministries throughout Europe and Asia, and interacting with Public Health England (PHE) and Defense Science and Technology Laboratory (DSTL) in the United Kingdom, the World Health Organization (WHO), the European Center for Disease Prevention and Control (ECDC), the European Agency for the Evaluation of Medical Products (EMEA), and governments in the Middle East, Asia, Australia, Israel, and Canada.
Our team develops procurement opportunities for our clients by helping federal agencies shape their requirements. In partnership with our strategic relationships who offer formal bid and proposal preparation services, we help guide the actual proposal preparation process including providing “red team” final proposal reviews through submission to ensure responsiveness to government requirements.
With the ever-evolving natures of government funding, industry regulation, and biological research, we have increasingly been called on to conduct in-depth reviews of company portfolios to both identify potential areas for portfolio growth, and to link current internal projects with external funding and marketing opportunities. This work includes both potential funding procurement opportunities that are currently being overlooked, as well as tactical analysis for initiatives such as intellectual property licensing and means of increasing the value of an institution’s research potential.